NASDAQ : VRCA
Verrica Pharmaceuticals Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.35 USD (Oct 30, 2026, 2:27 PM EDT) · Market cap 57.55M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 57.55M |
| Enterprise Value | 48.16M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 17.18M |
| Shares Outstanding | 17.18M |
| Shares Change (YoY) | +117.95% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.92% |
| Owned by Institutions (%) | 21.93% |
| Float | 12.41M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.90 |
| Forward PS | 1.91 |
| PB Ratio | 13.36 |
| P/TBV Ratio | 13.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.45 |
| Quick Ratio | 0.99 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.08 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -43.98% |
| Return on Invested Capital (ROIC) | -120.04% |
| Return on Capital Employed (ROCE) | -194.72% |
| Weighted Average Cost of Capital (WACC) | 17.65% |
| Revenue Per Employee | $398,961 |
| Profits Per Employee | -$410,303 |
| Employee Count | 76 |
| Asset Turnover | 0.81 |
| Inventory Turnover | 7.22 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.61 |
| 52-Week Price Change | -7.20% |
| 50-Day Moving Average | 4.41 |
| 200-Day Moving Average | 5.61 |
| Relative Strength Index (RSI) | 34.08 |
| Average Volume (20 Days) | 53,106 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 192,613 |
| Short Previous Month | 196,221 |
| Short % of Shares Out | 1.12% |
| Short % of Float | 1.55% |
| Short Ratio (days to cover) | 3.85 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 30.32M |
| Gross Profit | 11.43M |
| Operating Income | -26.43M |
| Pretax Income | -31.18M |
| Net Income | -31.18M |
| EBITDA | -25.96M |
| EBIT | -26.43M |
| Loss Per Share | -$1.88 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 11.20M |
| Total Debt | 1.81M |
| Net Cash | 9.39M |
| Net Cash Per Share | $0.55 |
| Equity (Book Value) | 4.31M |
| Book Value Per Share | 0.25 |
| Working Capital | 10.20M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -13.35M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 469,000 |
| Net Borrowing | -40.23M |
| Free Cash Flow | -13.35M |
| FCF Per Share | -$0.78 |
Margins
| Measure | Value |
|---|
| Gross Margin | 37.68% |
| Operating Margin | -87.18% |
| Pretax Margin | -102.84% |
| Profit Margin | -102.84% |
| EBITDA Margin | -85.63% |
| EBIT Margin | -87.18% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -117.95% |
| Shareholder Yield | -117.95% |
| Earnings Yield | -56.20% |
| FCF Yield | -23.19% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $13.83 |
| Price Target Difference | 312.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 7.95% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 25, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -13.16 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |